AR096332A1 - Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih - Google Patents
Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vihInfo
- Publication number
- AR096332A1 AR096332A1 ARP140101973A ARP140101973A AR096332A1 AR 096332 A1 AR096332 A1 AR 096332A1 AR P140101973 A ARP140101973 A AR P140101973A AR P140101973 A ARP140101973 A AR P140101973A AR 096332 A1 AR096332 A1 AR 096332A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered monocyclic
- cycloalkyl
- group
- halo
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 7
- 125000001475 halogen functional group Chemical group 0.000 abstract 7
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composiciones que comprenden al menos un derivado heterociclo tricíclico condensado y a procedimientos de uso de derivados heterociclos tricíclicos condensados para el tratamiento o prevención de la infección por el VIH en un sujeto. Reivindicación 1: Un compuesto que tiene la formula (1) y sales farmacéuticamente aceptables de las mismas, en la que: A es alquileno C₁₋₄, alquenileno C₂₋₄, arileno, cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo de 4 a 7 miembros, -O-, -NH-C(O)-, -C(O)NH- o -C(O)-; X es O, -N(alquilo C₁₋₆)- o -C(R¹⁰)(R¹¹), de forma que cuando X = O ó -N(alquilo C₁₋₆)-, R⁴, R⁵, R⁶ y R⁷ son cada uno distinto a -OR⁹, -N(R⁹)₂ o halo; cada aparición de m es de forma independiente de 0 ó 1; n es 0 ó 1, de forma que cuando n es 0, R⁴ y R⁵ no están presentes; R¹ es alquilo C₁₋₆, que está opcionalmente sustituido por hasta 3 grupos seleccionados cada uno de forma independiente de cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹, en el que dicho grupo cicloalquilo C₃₋₇, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros, dicho grupo heterocicloalquilo monocíclico de 4 a 6-miembros y dicho grupo arilo C₆₋₁₀ pueden estar cada uno opcional e independientemente sustituidos por uno o más grupos seleccionados cada uno de forma independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇ o heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹; R², R⁵, R⁶, R⁷, R¹⁰ y R¹¹ se seleccionan cada uno de forma independiente de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂ y -NHC(O)R⁹, en los que dicho grupo alquilo C₁₋₆ puede estar opcionalmente sustituido por uno o más grupos seleccionados cada uno de forma independiente de halo, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -SH o -S(alquilo C₁₋₆); R³ es H, alquilo C₁₋₆, cicloalquilo C₃₋₇, haloalquilo C₁₋₆, -C(O)R⁹, -C(O)N(R⁹)₂ y -NHC(O)R⁹, en los que dicho grupo alquilo C₁₋₆ puede estar opcionalmente sustituido por uno o más grupos seleccionados cada uno de forma independiente de halo, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -SH o -S(alquilo C₁₋₆); R⁴ es H, o R⁴ y R⁵ y el átomo de carbono común al que están unidos se unen para formar un grupo -C(O)- endocíclico; R⁸ se selecciona de alquilo C₁₋₆, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(heteroarilo monocíclico de 5 ó 6-miembros), -(alquileno C₁₋₃)ₘ-(heterocicloalquilo monocíclico de 4 a 6 miembros) y -(alquileno C₁₋₃)ₘ-(arilo C₆₋₁₀), en el que dicho grupo cicloalquilo C₃₋₇, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros, dicho grupo heterocicloalquilo monocíclico de 4 a 6 miembros y dicho grupo arilo C₆₋₁₀ pueden estar cada uno opcional e independientemente sustituidos con hasta 5 grupos, seleccionados cada uno de forma independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹; y cada aparición de R⁹ se selecciona de forma independiente de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, arilo C₆₋₁₀ y bencilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824739P | 2013-05-17 | 2013-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096332A1 true AR096332A1 (es) | 2015-12-23 |
Family
ID=51897679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101973A AR096332A1 (es) | 2013-05-17 | 2014-05-16 | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9643982B2 (es) |
| EP (2) | EP2997033B1 (es) |
| AR (1) | AR096332A1 (es) |
| AU (1) | AU2014267951A1 (es) |
| CY (1) | CY1119842T1 (es) |
| DK (1) | DK2997033T3 (es) |
| ES (1) | ES2656696T3 (es) |
| HK (1) | HK1248685A1 (es) |
| HR (1) | HRP20180081T1 (es) |
| HU (1) | HUE036384T2 (es) |
| LT (1) | LT2997033T (es) |
| ME (1) | ME02977B (es) |
| NO (1) | NO3058793T3 (es) |
| PL (1) | PL2997033T3 (es) |
| PT (1) | PT2997033T (es) |
| RS (1) | RS56701B1 (es) |
| SI (1) | SI2997033T1 (es) |
| TW (1) | TWI656122B (es) |
| WO (1) | WO2014183532A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3757105B1 (en) | 2014-08-22 | 2024-07-24 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
| TWI520963B (zh) * | 2014-12-24 | 2016-02-11 | 國立清華大學 | １，９－二氮萉衍生物及其製法 |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| EP3548031B1 (en) | 2016-12-02 | 2023-07-19 | Merck Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CN112088005A (zh) * | 2018-04-27 | 2020-12-15 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| CR20200645A (es) | 2018-05-31 | 2021-02-05 | Shionogi & Co | Derivado policiclíco de piridona |
| SMT202400330T1 (it) | 2018-05-31 | 2024-09-16 | Shionogi & Co | Derivati policiclici della carbammoilpiridone per il trattamento dell'hiv |
| US11884683B2 (en) | 2018-06-05 | 2024-01-30 | Merck Sharp & Dohme Llc | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| IL278063B2 (en) | 2018-06-21 | 2025-08-01 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| US12421235B2 (en) | 2020-09-30 | 2025-09-23 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202408533A (zh) | 2021-01-19 | 2024-03-01 | 美商基利科學股份有限公司 | 經取代之吡啶并三𠯤化合物及其用途 |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2383262T3 (es) | 2001-08-10 | 2012-06-19 | Shionogi & Co., Ltd. | Agente antiviral |
| EP1441735B1 (en) | 2001-10-26 | 2006-02-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| JP4351053B2 (ja) | 2001-10-26 | 2009-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬 |
| JP4523281B2 (ja) | 2002-01-17 | 2010-08-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類 |
| JP4733986B2 (ja) | 2002-12-27 | 2011-07-27 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物 |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| NZ549449A (en) | 2004-03-09 | 2009-05-31 | Merck & Co Inc | HIV Integrase inhibitors |
| AU2005221864A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
| JP2007528394A (ja) | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| JP2007528396A (ja) * | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| EP1866313A1 (en) | 2005-03-31 | 2007-12-19 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| US7897592B2 (en) | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| NZ598766A (en) | 2009-10-13 | 2013-09-27 | Elanco Animal Health Ireland | Macrocyclic integrase inhibitors |
| NZ601847A (en) * | 2010-02-26 | 2014-03-28 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| CN102958935B (zh) | 2010-04-02 | 2015-12-09 | 爱尔兰詹森科学公司 | 大环整合酶抑制剂 |
-
2014
- 2014-04-18 PT PT147981880T patent/PT2997033T/pt unknown
- 2014-04-18 SI SI201430563T patent/SI2997033T1/en unknown
- 2014-04-18 LT LTEP14798188.0T patent/LT2997033T/lt unknown
- 2014-04-18 DK DK14798188.0T patent/DK2997033T3/da active
- 2014-04-18 EP EP14798188.0A patent/EP2997033B1/en active Active
- 2014-04-18 HU HUE14798188A patent/HUE036384T2/hu unknown
- 2014-04-18 HR HRP20180081TT patent/HRP20180081T1/hr unknown
- 2014-04-18 WO PCT/CN2014/075685 patent/WO2014183532A1/en not_active Ceased
- 2014-04-18 EP EP17201148.8A patent/EP3330272B1/en active Active
- 2014-04-18 RS RS20180010A patent/RS56701B1/sr unknown
- 2014-04-18 ME MEP-2018-4A patent/ME02977B/me unknown
- 2014-04-18 US US14/892,754 patent/US9643982B2/en active Active
- 2014-04-18 ES ES14798188.0T patent/ES2656696T3/es active Active
- 2014-04-18 PL PL14798188T patent/PL2997033T3/pl unknown
- 2014-04-18 AU AU2014267951A patent/AU2014267951A1/en not_active Abandoned
- 2014-05-15 TW TW103117219A patent/TWI656122B/zh not_active IP Right Cessation
- 2014-05-16 AR ARP140101973A patent/AR096332A1/es not_active Application Discontinuation
-
2015
- 2015-01-28 NO NO15704618A patent/NO3058793T3/no unknown
-
2018
- 2018-01-24 CY CY20181100097T patent/CY1119842T1/el unknown
- 2018-06-26 HK HK18108172.3A patent/HK1248685A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201524978A (zh) | 2015-07-01 |
| EP2997033B1 (en) | 2017-11-15 |
| HK1248685A1 (en) | 2018-10-19 |
| EP2997033A1 (en) | 2016-03-23 |
| EP3330272A1 (en) | 2018-06-06 |
| PL2997033T3 (pl) | 2018-04-30 |
| PT2997033T (pt) | 2018-01-25 |
| EP3330272B1 (en) | 2021-02-17 |
| ES2656696T3 (es) | 2018-02-28 |
| DK2997033T3 (da) | 2018-01-29 |
| US9643982B2 (en) | 2017-05-09 |
| EP2997033A4 (en) | 2016-10-26 |
| RS56701B1 (sr) | 2018-03-30 |
| SI2997033T1 (en) | 2018-04-30 |
| US20160108059A1 (en) | 2016-04-21 |
| NO3058793T3 (es) | 2018-03-17 |
| CY1119842T1 (el) | 2018-06-27 |
| AU2014267951A1 (en) | 2015-11-19 |
| WO2014183532A1 (en) | 2014-11-20 |
| ME02977B (me) | 2018-10-20 |
| LT2997033T (lt) | 2018-02-12 |
| TWI656122B (zh) | 2019-04-11 |
| HRP20180081T1 (hr) | 2018-02-23 |
| HUE036384T2 (hu) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR087791A1 (es) | Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR092306A1 (es) | Antibacterianos de fenicol | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR089285A1 (es) | Derivados de betulina | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |